Category Regulatory

Multi Radiance Medical Expands FDA Clearance for Lateral Epicondylitis After Triple-Blind Trial

Multi Radiance Medical Secures Expanded FDA Clearance for Lateral Epicondylitis Following Successful Triple-Blind Clinical Trial Multi Radiance Medical, a global leader in Super Pulsed Laser technology and photobiomodulation research, has announced that the U.S. Food and Drug Administration has granted…

Read MoreMulti Radiance Medical Expands FDA Clearance for Lateral Epicondylitis After Triple-Blind Trial

Biogen’s Salanersen Granted FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Biogen’s Salanersen Granted FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy Biogen Inc. (Nasdaq: BIIB) has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to salanersen, an investigational antisense oligonucleotide (ASO) being developed for…

Read MoreBiogen’s Salanersen Granted FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Verastem Oncology Receives FDA Fast Track for VS-7375 in Non-Small Cell Lung Cancer

Verastem Oncology’s VS-7375 Receives FDA Fast Track Designation for KRAS G12D-Mutated Non-Small Cell Lung Cancer Verastem Oncology, a biopharmaceutical company focused on developing targeted therapies for cancers driven by the RAS/MAPK signaling pathway, has announced that the U.S. Food and…

Read MoreVerastem Oncology Receives FDA Fast Track for VS-7375 in Non-Small Cell Lung Cancer

Terremoto Biosciences Receives FDA Fast Track for TER-2013 AKT1-Selective Inhibitor in Breast Cancer

Terremoto Biosciences Receives FDA Fast Track Designation for TER-2013 in Advanced HR+/HER2- Breast Cancer Terremoto Biosciences, a biotechnology company focused on developing highly targeted small-molecule therapies for cancer, has announced that the U.S. Food and Drug Administration (FDA) has granted…

Read MoreTerremoto Biosciences Receives FDA Fast Track for TER-2013 AKT1-Selective Inhibitor in Breast Cancer

Shionogi Secures FDA Approval for XOCOVA® as First Oral Treatment to Help Prevent COVID-19 After Exposure

Shionogi’s XOCOVA® Becomes First FDA-Approved Oral Treatment for Preventing COVID-19 Following Exposure Shionogi & Co., Ltd. has announced a significant regulatory milestone for its antiviral medicine XOCOVA® (ensitrelvir), with the U.S. Food and Drug Administration (FDA) granting approval for the…

Read MoreShionogi Secures FDA Approval for XOCOVA® as First Oral Treatment to Help Prevent COVID-19 After Exposure

FDA Approves FoundationOne CDx Tests as Companion Diagnostics for TALZENNA + XTANDI in HRR-Mutated mCRPC

FDA Approves FoundationOne CDx Tests as Companion Diagnostics for TALZENNA and XTANDI in HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer Foundation Medicine, a global precision medicine company dedicated to advancing personalized cancer care, has announced a significant regulatory milestone with the…

Read MoreFDA Approves FoundationOne CDx Tests as Companion Diagnostics for TALZENNA + XTANDI in HRR-Mutated mCRPC

Veracyte OPTIMA Trial Shows Prosigna Identifies Breast Cancer Patients Who Can Avoid Chemotherapy

Veracyte’s Prosigna Test Shows Practice-Changing Results in Early Breast Cancer at ASCO 2026 OPTIMA Trial Veracyte, Inc., a leading cancer diagnostics company, has announced highly significant results from the independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter…

Read MoreVeracyte OPTIMA Trial Shows Prosigna Identifies Breast Cancer Patients Who Can Avoid Chemotherapy

Merck’s Calderasib Receives FDA Breakthrough Therapy Designation for KRAS G12C-Mutant Non-Small Cell Lung Cancer

Merck’s Investigational KRAS Inhibitor Calderasib Receives FDA Breakthrough Therapy Designation for First-Line KRAS G12C-Mutated Lung Cancer Merck, known as MSD outside the United States and Canada, has announced a significant regulatory milestone for its oncology pipeline with the U.S. Food…

Read MoreMerck’s Calderasib Receives FDA Breakthrough Therapy Designation for KRAS G12C-Mutant Non-Small Cell Lung Cancer